SG11201811100RA - Treatment of retinal vascular disease using progenitor cells - Google Patents

Treatment of retinal vascular disease using progenitor cells

Info

Publication number
SG11201811100RA
SG11201811100RA SG11201811100RA SG11201811100RA SG11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA SG 11201811100R A SG11201811100R A SG 11201811100RA
Authority
SG
Singapore
Prior art keywords
international
johnson
rule
pennsylvania
applicant
Prior art date
Application number
SG11201811100RA
Inventor
Ian Harris
Nadine Sophia Dejneka
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201811100RA publication Critical patent/SG11201811100RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/51Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0605Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 January 2018 (11.01.2018) W I PO I PCT omit n OH 10 0 011101101111 OM IMMO 011 (10) International Publication Number WO 2018/009385 Al (51) International Patent Classification: A61K 35/51 (2015.01) A61P 27/02 (2006.01) (21) International Application Number: PCT/US2017/039660 (22) International Filing Date: 28 June 2017 (28.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/358,389 05 July 2016 (05.07.2016) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: HARRIS, Ian; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). DEJNEKA, Nadine Sophia; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). (74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) pp 11 as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) O 00 (54) Title: TREATMENT OF RETINAL VASCULAR DISEASE USING PROGENITOR CELLS 1-1 0 (57) : Methods and compositions for treating ophthalmic disease, reducing retinal neovascularization and retinal vascular \" leakage using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed.
SG11201811100RA 2016-07-05 2017-06-28 Treatment of retinal vascular disease using progenitor cells SG11201811100RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662358389P 2016-07-05 2016-07-05
PCT/US2017/039660 WO2018009385A1 (en) 2016-07-05 2017-06-28 Treatment of retinal vascular disease using progenitor cells

Publications (1)

Publication Number Publication Date
SG11201811100RA true SG11201811100RA (en) 2019-01-30

Family

ID=59363222

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811100RA SG11201811100RA (en) 2016-07-05 2017-06-28 Treatment of retinal vascular disease using progenitor cells

Country Status (16)

Country Link
US (1) US20180015129A1 (en)
EP (1) EP3481405A1 (en)
JP (1) JP2019524688A (en)
KR (1) KR20190026758A (en)
CN (1) CN109414460A (en)
AR (1) AR108972A1 (en)
AU (1) AU2017291707A1 (en)
BR (1) BR112019000059A2 (en)
CA (1) CA3029997A1 (en)
MA (1) MA45623A (en)
MX (1) MX2019000050A (en)
PH (1) PH12018502704A1 (en)
RU (1) RU2019102933A (en)
SG (1) SG11201811100RA (en)
TW (1) TW201811344A (en)
WO (1) WO2018009385A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114712393B (en) * 2020-12-18 2024-01-19 中国人民解放军海军军医大学第三附属医院 Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707643A (en) 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5718922A (en) 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
CA2370330C (en) 1999-04-16 2009-01-20 Wm. Marsh Rice University Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
ES2564045T3 (en) 2003-06-27 2016-03-17 DePuy Synthes Products, Inc. Postpartum derived cells for use in the treatment of heart disease and the circulatory system
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
SG170789A1 (en) * 2005-12-28 2011-05-30 Ethicon Inc Treatment of peripheral vascular disease using postpartum-derived cells

Also Published As

Publication number Publication date
AR108972A1 (en) 2018-10-17
AU2017291707A1 (en) 2019-01-03
US20180015129A1 (en) 2018-01-18
BR112019000059A2 (en) 2019-10-01
MA45623A (en) 2019-05-15
CN109414460A (en) 2019-03-01
RU2019102933A (en) 2020-08-05
JP2019524688A (en) 2019-09-05
KR20190026758A (en) 2019-03-13
WO2018009385A1 (en) 2018-01-11
TW201811344A (en) 2018-04-01
PH12018502704A1 (en) 2019-11-11
EP3481405A1 (en) 2019-05-15
MX2019000050A (en) 2019-05-02
CA3029997A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201909949XA (en) Targeted immunotolerance
SG11201811432WA (en) Rna for cancer therapy
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201809751XA (en) Egfr inhibitor compounds
SG11201805001UA (en) Method of treating influenza a
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201900361RA (en) Methods of treating prostate cancer
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same